Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. - Wikidata - wikimedia - TriplyDB

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

http://www.wikidata.org/entity/Q35249697

about

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases Splice Variants of Androgen Receptor and Prostate Cancer Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Persistent androgen receptor addiction in castration-resistant prostate cancer Targeting molecular resistance in castration-resistant prostate cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Abiraterone in prostate cancer: a new angle to an old problem Abiraterone in the treatment of metastatic castration-resistant prostate cancer Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Androgen receptor on the move: boarding the microtubule expressway to the nucleus Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation Androgens and prostate disease Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression Recent progress in pharmaceutical therapies for castration-resistant prostate cancer Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Androgen biosynthesis in castration-resistant prostate cancer Free testosterone drives cancer aggressiveness: evidence from US population studies AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer Emerging data on androgen receptor splice variants in prostate cancer How Precisely Can Prostate Cancer Be Managed?Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells Characterization of niphatenones that inhibit androgen receptor N-terminal domain Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.Androgen receptor splice variants determine taxane sensitivity in prostate cancer.The link between androgen receptor splice variants and castration-resistant prostate cancer.Androgen receptor splice variants and prostate cancer: From bench to bedside.Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?

P2860

Q21558502-75F83190-8D64-46A4-8C5C-2C6B6974487F Q26740592-6F3CF915-0BF4-4B89-83AB-9C90B05D8DDC Q26751237-2C33BF0E-7059-431B-B6D0-60EAD44A5C13 Q26774221-AFB3A37F-9004-473D-810D-71257505E840 Q26777163-B02F432C-364B-476A-9B02-88E6CF626717 Q26795445-03C0B0C6-3048-4AA1-BBA3-E62A990AC63B Q26796568-BA69CE65-60D9-45D8-B8A6-63B9C7F0A43C Q26796704-4A67DF8D-6B3D-4419-A896-F90AF02EED17 Q26828810-CBB86A63-C990-49DB-8435-8A4B6B7F12F1 Q26853635-FD41BABF-689B-4987-AD59-5F2C595B2BCA Q26858922-E5599088-383A-485E-AF57-C253DDE6379F Q26862560-1248D8AD-409D-4445-ADA9-3836CCEC3F2E Q27007208-0E923F9C-5AB3-4F0C-B133-258D96BAC260 Q27010093-28A06922-099A-4F51-93E5-E2BDFE6A7FFA Q27010542-B6548EF3-4EA6-4587-888A-0393744EE37E Q27011642-0831DCAD-1BD7-49A0-A0E9-A7F95B057993 Q27022288-270B7F80-121A-45C4-8A9D-4BF0EB116A3D Q27022567-083BB7F8-4670-4C16-A531-F1137021154F Q27024775-60B1CB59-5ADB-4F02-97A2-94076D33541B Q27026044-40BEB6DB-8900-4670-941D-F197E8B21117 Q27324026-9E67F72F-2EBF-406D-8A59-AD5C9B29294D Q27853062-03C66D1F-E45A-4301-BD0D-5E4DB66968E0 Q28077830-B1C3E8A1-828B-47B3-B6AD-EA644075DC68 Q28078942-2BF912D8-4AEB-4AB1-98D5-505D7D4C95C0 Q28539233-1541CE79-4A8A-4603-8342-2654387C76B8 Q28543404-3DA1766B-3B31-4882-8B8F-AD1A94022E68 Q28607383-7ADD6E6B-FA78-42FA-AF5B-3B17C236442E Q30008838-B72FD162-83F7-44CF-8049-BCE4B3981836 Q30370955-B0AEA146-1AD7-47F6-BDBA-42D122711F57 Q30528764-709E8587-EEF5-4FAA-AEBF-B1FD781ACD15 Q30554439-8C7E6437-1DC1-4399-9589-F45A33013CDC Q30563985-3295690D-64FC-4A55-AC17-035110EC1B95 Q30577613-D011684E-C64D-4C03-A368-78F11AE6FF67 Q30618562-AC16DDD3-3F1F-4749-A1F8-06CE7EE935DA Q33567024-5FBB1ABB-178F-4FE2-A4A8-E89EDBEBF9E3 Q33589156-E08CF483-C83E-4176-8A05-5EA67075B053 Q33621403-D8776F09-D578-46B7-A80D-92D42B53BF5C Q33656820-660E28DC-2606-4375-B54A-0F37995611EF Q33688956-D20D1494-8049-4265-BCFE-ED1B14BC0D59 Q33775717-42A131F4-931C-4172-B872-DA73F03D16F2

P2860

Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

http://www.wikidata.org/entity/Q35249697

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@ast

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@en

type

label

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@ast

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@en

prefLabel

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@ast

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@en

P1433

Q35249697-84A25E97-4AB6-4EAC-BD1B-3B4CA4C59042

P1476

Q35249697-B3BAFAAC-1927-45AE-92F2-539A48261278

P2093

Q35249697-118036E4-9112-436B-95BC-118E6ABC6E36

Q35249697-2EB5653C-065B-484A-8EDA-DB58F73D31D8

Q35249697-5D1461D4-4C56-423B-8CB9-9BA0BEEF01DB

Q35249697-B623BF43-D63A-4A83-A819-558B0058122A

Q35249697-BDC047EF-2A14-47E5-9A0C-8B98041C6251

Q35249697-D256BEE5-29FB-4910-9788-E8ACAB0C4EFE

Q35249697-DA28D591-B344-4C4A-BF1E-F0282EBBACB5

Q35249697-FA7C7B3B-97A5-401D-93CC-68DD0A81492F

P2860

Q35249697-00F40CC6-F1A6-4DC8-9C0B-84098D25D369

Q35249697-03762705-9208-4D8D-A74E-98EAD5BE60FC

Q35249697-0717B877-B05C-448F-A99F-F91A163743B0

Q35249697-0827F9CA-E0BC-46BC-B708-A4211AC9D6DB

Q35249697-111C9964-A196-48E8-8A5A-592C2E279459

Q35249697-361098AA-BEC5-43C6-974E-BB5901AC879B

Q35249697-3A945B53-E3F1-4068-8357-269492B3282F

Q35249697-555AD798-9B73-447A-92A9-64B770691AA4

Q35249697-5CD0E51A-61F2-485C-B9C6-2FEF684B9929

Q35249697-5FC180B7-8CF2-426D-9F59-57E06520B012

P304

Q35249697-844710AF-514E-472D-9B04-F3B57E35AFA6

P31

Q35249697-D038B571-1D2D-46DD-86CD-FA36BC179857

P356

Q35249697-1135E62B-BFCB-4E5F-B638-9E7CCF3BDD91

P407

Q35249697-0F59E5E6-A61B-4870-A025-89D9F5C810E7

P433

Q35249697-49EF6FE2-0D3C-4130-AF00-249D8EC0FE2A

P478

Q35249697-749C9AB4-05E0-4DE7-B8C0-A5BA4B9EF7F0

P577

Q35249697-75EA6100-DAF4-41EF-AE8F-47E00FDC1FFB

P5875

Q35249697-B7A65485-506A-4A74-84BB-5540D7ADE0D2

P698

Q35249697-AA28C6EE-8A88-4D15-ABAA-3F9FF9071424

P921

Q35249697-1D9974EE-83AD-4A07-8F3B-FA1F045CECF1

P932

Q35249697-530A743E-55EC-423B-8E9A-1278B938541C

P356

1078-0432.CCR-11-0728

P1433

Clinical Cancer Research

P1476

Resistance to CYP17A1 inhibiti ...... ogen receptor splice variants.

@en

P2093

Alvin M Matsumoto

http://www.w3.org/2001/XMLSchema#string

Brett T Marck

http://www.w3.org/2001/XMLSchema#string

Elahe A Mostaghel

http://www.w3.org/2001/XMLSchema#string

Peter S Nelson

http://www.w3.org/2001/XMLSchema#string

R Bruce Montgomery

http://www.w3.org/2001/XMLSchema#string

Robert L Vessella

http://www.w3.org/2001/XMLSchema#string

Stephen Balk

http://www.w3.org/2001/XMLSchema#string

Stephen R Plymate

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Molecular determinants of resistance to antiandrogen therapy

Abiraterone and increased survival in metastatic prostate cancer

Glucocorticoid receptor signaling and prostate cancer.

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

P304

5913-5925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0728

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51538847

http://www.w3.org/2001/XMLSchema#string

P698

21807635

http://www.w3.org/2001/XMLSchema#string

P921

P932

3184252

http://www.w3.org/2001/XMLSchema#string